The Czech National Non-Hodgkin Lymphoma (NHL) Registry, "NiHiL" (registered on ClinicalTrials.gov under NCT03199066), was established in 1999 by the Czech Lymphoma Study Group. Its mission is to monitor epidemiological data, treatment modalities, and patient outcomes in real-world clinical practice. As of mid-2025, the registry has documented more than 25,000 unique NHL cases, making it one of the largest national lymphoma registries in the world.

In recent years, the registry has captured approximately 70% of all NHL patients in the Czech Republic. These patients are treated at one of the eight university-based centers for intensive hematology care or at collaborating regional hospitals.

NiHiL has contributed significantly to numerous clinical and translational research studies that have shaped the modern understanding of lymphoma epidemiology, risk stratification, and therapeutic outcomes (for details, see "Publications"). These achievements highlight the registry’s importance not only as a tool for benchmarking clinical practice, but also as a robust scientific resource for advancing lymphoma research on an international scale.

Centers of hematology care in the Czech Republic by annual contribution to the NiHiL registry.

The Czech Lymphoma Study Group (CLSG) is a professional association of physicians, researchers, and other healthcare and non-healthcare specialists in the Czech Republic. The group focuses on the diagnosis, treatment, and research of malignant lymphomas.

The main objectives of CLSG are:

1. Development of diagnostic and treatment protocols. The primary goal of the CLSG is to standardize treatment approaches across centers and ensure that the latest clinical research findings are translated into routine practice. The group issues expert recommendations that contribute to the unification of care for lymphoma patients. Current diagnostic and therapeutic guidelines are available on this website.
2. Design and organization of clinical studies. The CLSG actively participates in the design and management of multicenter clinical trials. Information on ongoing and accruing trials at CLSG centers is regularly updated and accessible on our website.
3. Analyses and presentation of lymphoma treatment results. Treatment outcomes are monitored through data analysis from the NiHiL registry. Findings are published in peer-reviewed international journals and presented at major international conferences (see details here).
4. Education in the field of lymphomas. The CLSG organizes professional conferences and is actively engaged in the education of young physicians and other specialists in hematologic oncology.
5. Support for lymphoma research. The CLSG fosters research initiatives that advance knowledge and innovation in the field.

Through its long-standing activities, the CLSG represents a key platform for sharing expertise, standardizing treatment, and supporting research into lymphoproliferative diseases in the Czech Republic. Our work significantly contributes to improving the quality of patient care and strengthening international collaboration within the Czech hematology community.

Membership: If you are not yet a member of the Czech Lymphoma Study Group (CLSG) and would like to join, please contact the Datacenter (office@lymphoma.cz). Membership provides access to the CLSG members’ area and offers opportunities to participate in collaborative clinical and research initiatives in the field of lymphoma. We warmly welcome all healthcare professionals with an interest in lymphoma diagnostics, treatment, and research, and encourage active involvement in advancing patient care and scientific knowledge.